miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer

Yoshitaro Shindo, Shoichi Hazama, Yusuke Nakamura, Yuka Inoue, Shinsuke Kanekiyo, Nobuaki Suzuki, Hiroko Takenouchi, Ryouichi Tsunedomi, Masao Nakajima, Tomio Ueno, Shigeru Takeda, Shigefumi Yoshino, Kiyotaka Okuno, Yusuke Fujita, Yoshihiko Hamamoto, Yutaka Kawakami, Masaaki Oka, Hiroaki Nagano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A* 2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A* 2402-matched group and 10 patients from the HLA-A* 2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A* 2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A* 2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.

Original languageEnglish
Pages (from-to)1355-1362
Number of pages8
JournalOncology Letters
Volume14
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

MicroRNAs
Colorectal Neoplasms
Vaccines
Biomarkers
HLA Antigens
Research Design
Peptides
Tumor Microenvironment
Microarray Analysis
Immunotherapy
Neoplasms
Vaccination

Keywords

  • Colorectal cancer
  • Efficacy
  • MicroRNA
  • Peptide vaccine
  • Predictive biomarker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Shindo, Y., Hazama, S., Nakamura, Y., Inoue, Y., Kanekiyo, S., Suzuki, N., ... Nagano, H. (2017). miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncology Letters, 14(2), 1355-1362. https://doi.org/10.3892/ol.2017.6303

miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. / Shindo, Yoshitaro; Hazama, Shoichi; Nakamura, Yusuke; Inoue, Yuka; Kanekiyo, Shinsuke; Suzuki, Nobuaki; Takenouchi, Hiroko; Tsunedomi, Ryouichi; Nakajima, Masao; Ueno, Tomio; Takeda, Shigeru; Yoshino, Shigefumi; Okuno, Kiyotaka; Fujita, Yusuke; Hamamoto, Yoshihiko; Kawakami, Yutaka; Oka, Masaaki; Nagano, Hiroaki.

In: Oncology Letters, Vol. 14, No. 2, 2017, p. 1355-1362.

Research output: Contribution to journalArticle

Shindo, Y, Hazama, S, Nakamura, Y, Inoue, Y, Kanekiyo, S, Suzuki, N, Takenouchi, H, Tsunedomi, R, Nakajima, M, Ueno, T, Takeda, S, Yoshino, S, Okuno, K, Fujita, Y, Hamamoto, Y, Kawakami, Y, Oka, M & Nagano, H 2017, 'miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer', Oncology Letters, vol. 14, no. 2, pp. 1355-1362. https://doi.org/10.3892/ol.2017.6303
Shindo, Yoshitaro ; Hazama, Shoichi ; Nakamura, Yusuke ; Inoue, Yuka ; Kanekiyo, Shinsuke ; Suzuki, Nobuaki ; Takenouchi, Hiroko ; Tsunedomi, Ryouichi ; Nakajima, Masao ; Ueno, Tomio ; Takeda, Shigeru ; Yoshino, Shigefumi ; Okuno, Kiyotaka ; Fujita, Yusuke ; Hamamoto, Yoshihiko ; Kawakami, Yutaka ; Oka, Masaaki ; Nagano, Hiroaki. / miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. In: Oncology Letters. 2017 ; Vol. 14, No. 2. pp. 1355-1362.
@article{c725e867a0944049a5b5ee742939bae0,
title = "miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer",
abstract = "MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A* 2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A* 2402-matched group and 10 patients from the HLA-A* 2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A* 2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A* 2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.",
keywords = "Colorectal cancer, Efficacy, MicroRNA, Peptide vaccine, Predictive biomarker",
author = "Yoshitaro Shindo and Shoichi Hazama and Yusuke Nakamura and Yuka Inoue and Shinsuke Kanekiyo and Nobuaki Suzuki and Hiroko Takenouchi and Ryouichi Tsunedomi and Masao Nakajima and Tomio Ueno and Shigeru Takeda and Shigefumi Yoshino and Kiyotaka Okuno and Yusuke Fujita and Yoshihiko Hamamoto and Yutaka Kawakami and Masaaki Oka and Hiroaki Nagano",
year = "2017",
doi = "10.3892/ol.2017.6303",
language = "English",
volume = "14",
pages = "1355--1362",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer

AU - Shindo, Yoshitaro

AU - Hazama, Shoichi

AU - Nakamura, Yusuke

AU - Inoue, Yuka

AU - Kanekiyo, Shinsuke

AU - Suzuki, Nobuaki

AU - Takenouchi, Hiroko

AU - Tsunedomi, Ryouichi

AU - Nakajima, Masao

AU - Ueno, Tomio

AU - Takeda, Shigeru

AU - Yoshino, Shigefumi

AU - Okuno, Kiyotaka

AU - Fujita, Yusuke

AU - Hamamoto, Yoshihiko

AU - Kawakami, Yutaka

AU - Oka, Masaaki

AU - Nagano, Hiroaki

PY - 2017

Y1 - 2017

N2 - MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A* 2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A* 2402-matched group and 10 patients from the HLA-A* 2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A* 2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A* 2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.

AB - MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A* 2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A* 2402-matched group and 10 patients from the HLA-A* 2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A* 2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A* 2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.

KW - Colorectal cancer

KW - Efficacy

KW - MicroRNA

KW - Peptide vaccine

KW - Predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=85021733824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021733824&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6303

DO - 10.3892/ol.2017.6303

M3 - Article

AN - SCOPUS:85021733824

VL - 14

SP - 1355

EP - 1362

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -